Irene O L Ng

Targets

• AMPK 1
• PD-1 1

Filled chips are declared by the researcher; the others come from publications (number of works).

Now

Trials, publications and grants since Nov 2024.

• Publication

  Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma.

  Molecular cancer, Jun 2026

• Publication

  Tumor microenvironment and metabolic reprogramming in MASLD-related hepatocellular carcinoma.

  Trends in molecular medicine, May 2026

• Publication

  Repurposing Resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression.

  Hepatology (Baltimore, Md.), Jan 2026

• Publication

  Cancer stem cells in hepatocellular carcinoma: platforms, updates, challenges and future perspectives.

  Cancer biology & medicine, Dec 2025

• Publication

  Spatiotemporal dynamics of T cells in peripheral blood and tumor underlying differential responses to neoadjuvant PD-1 blockade in hepatocellular carcinoma.

  Journal for immunotherapy of cancer, Dec 2025

• Publication

  Prospective analysis on the outcomes of histotripsy for primary and metastatic liver tumors.

  International journal of surgery (London, England), Nov 2025

• Publication

  Mevalonate pathway promotes liver cancer by suppressing ferroptosis through CoQ10 production and selenocysteine-tRNA modification.

  Journal of hepatology, Jul 2025

Affiliations

• University of Hong Kong
• Queen Mary Hospital

Co-authors

Who links you

Enter another researcher's profile link or ID to see who has published with both of you.